Skip to main content

Table 3 Multivariate analysis of survival for patients with ANPC

From: Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma

  All population Cycles <4 population Cycles > =4 population
Variable OS DMFS OS DMFS OS DMFS
Leucopenia      
Mild VS Absent      
HR(95 %CI)a 0.69(0.56-0.85) 0.77(0.61-0.96) 0.70(0.55-0.89) 0.88(0.63-1.23) 0.73(0.46-1.15) 0.61(0.40-0.94)
P <0.001 0.023 0.003 0.452 0.174 0.025
Severe VS Absent      
HR(95 %CI)a 0.75(0.59-0.95) 0.99(0.77-1.29) 0.82(0.60-1.11) 0.79(0.61-1.03) 0.97(0.74-1.27) 0.84(0.53-1.32)
P 0.019 0.995 0.204 0.083 0.828 0.446
Mild VS Severe      
HR(95 %CI)a 0.93(0.77-1.11) 0.77(0.64-0.93) 0.85(0.66-1.09) 0.90(0.68-1.19 0.71(0.46-1.07 0.73(0.56-0.96)
P 0.416 0.006 0.204 0.469 0.108 0.026
Gender       
HR(95 %CI) 0.67(0.55-0.81) 0.70(0.58-0.86) 0.66(0.52-0.84) 0.73(0.57-0.93) 0.66(0.48-0.91) 0.68(0.49-0.94)
P <0.001 <0.001 0.001 0.013 0.010 0.019
Age       
HR(95 %CI) 1.82(1.57-2.12) 1.05(0.89-1.23) 1.88(1.55-2.28) 1.09(0.89-1.34 1.71(1.34-2.17) 1.03(0.81-1.33)
P <0.001 0.532 <0.001 0.367 <0.001 0.783
T-classification       
HR(95 %CI) 1.49(1.35-1.66) 1.33(1.19-1.47) 1.51(1.33-1.72) 1.36(1.19-1.56) 1.49(1.26-1.76) 1.27(1.08-1.51)
P <0.001 <0.001 <0.001 <0.001 <0.001 0.005
N-classification       
HR(95CI) 1.77(1.62-1.93) 1.78(1.62-1.97) 1.92(1.71-2.16) 1.92(1.68-2.18) 1.56(1.35-1.80) 1.63(1.40-1.90)
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
  1. Abbreviations: OS: overall survival; DMFS: distant metastasis-free survival; HR: hazard ratio; CI: confidence interval; ANPC: advanced nasopharyngeal carcinoma
  2. aAdjusted for age (<45 and ≥45 years old), sex, T classification (T1/T2/T3/T4), N classification (N0/N1/N2/N3), pathological type, type of radiotherapy, type of chemotherapy, and paclitaxel use